PMV Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
PMV Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • PMV Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$19.2M, a 15.5% decline year-over-year.
  • PMV Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$51.5M, a 29.1% increase year-over-year.
  • PMV Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$69M, a 5.94% increase from 2022.
  • PMV Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$73.3M, a 26.7% decline from 2021.
  • PMV Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$57.8M, a 68% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$51.5M -$19.2M -$2.59M -15.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$48.9M -$1.21M +$16.2M +93% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$65.1M -$15.3M +$3.86M +20.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$69M -$15.8M +$3.59M +18.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$72.5M -$16.6M +$1.59M +8.72% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$74.1M -$17.4M -$126K -0.73% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$74M -$19.1M -$695K -3.77% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$73.3M -$19.3M -$986K -5.37% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$72.3M -$18.2M -$3.22M -21.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$69.1M -$17.3M -$4.44M -34.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$64.7M -$18.4M -$6.83M -58.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$57.8M -$18.4M -$7.91M -75.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$49.9M -$15M -$6.25M -71.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$43.7M -$12.9M -$4.91M -61.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$38.8M -$11.6M -$4.35M -59.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$34.4M -$10.5M -$3.41M -48.3% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 -$31M -$8.76M -$2.59M -41.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$28.4M -$7.97M -$1.84M -30% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$26.6M -$7.26M -$1.25M -20.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$25.4M -$7.05M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$6.18M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$6.13M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-13
Q1 2019 -$6M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.